Identification of new molecular markers for multiple myeloma paves path for more precise therapies

by Centro de Investigación Médica Aplicada (CIMA) Universidad de Navarra

edited by Stephanie Baum, reviewed by Robert Egan

Stephanie Baum

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Senior Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

proofread

The GIST Add as preferred source

Researchers at Cima and Clinica Universidad de Navarra have identified new molecular mechanisms underlying multiple myeloma. This type of hematologic cancer, which affects the bone marrow, is characterized by its resistance to treatment, leading to relapses in patients. The researchers' paper is published in the journal Blood.

The study focused on analyzing which transcription factors (key proteins that regulate gene activation) are essential in the development of multiple myeloma.

This research, conducted at the Cancer Center Clínica Universidad de Navarra, builds on previous work that studied the complete epigenome of myeloma.

"In those studies, we discovered that transcription factors could play a key role in the epigenomic alterations of multiple myeloma. In the study we have just published, we demonstrate the role of IRF2, a transcription factor whose role in this disease was previously unknown and which may become a promising therapeutic target," explained Dr. Nahia Gómez-Echarte, a postdoctoral researcher at CIMA and first author of the study.

"We have also confirmed that its expression is a good biomarker because it allows us to stratify patients based on better or worse prognoses," said Xabier Agirre, principal investigator of the Cima Epigenetics Group and co-director of the study, along with Dr. Felipe Prósper and Dr. Edurne San José-Enériz.

Predicting response to treatment

The study analyzed 230 transcription factors identified using computational tools. Subsequently, 54 factors that were expressed in myeloma cells were selected. For each of these transcription factors, 10 different CRISPR guides were designed to determine whether inhibiting these factors was key to the viability of myeloma cells. This analysis identified 22 factors that are potentially essential for the development of this type of cancer.

Among these transcription factors, scientists at Cima demonstrated that IRF2 plays key biological roles, such as regulating necroptosis (a type of cell death), migration and cell cycle control in multiple myeloma. Furthermore, the study reveals that IRF2 expression levels allow for better stratification of patients, distinguishing those with a better or worse prognosis.

Agirre noted, "Incorporating this biomarker into current multiple myeloma classification systems could improve the ability to predict patients' response to treatments."

Publication details

Nahia Gómez-Echarte et al, IRF2 is an essential transcription factor with pathogenic and prognostic impact in multiple myeloma, Blood (2026). DOI: 10.1182/blood.2025029422

Journal information: Blood

Key medical concepts

Multiple MyelomaBiomarkersNecroptosis

Clinical categories

Oncology Provided by Centro de Investigación Médica Aplicada (CIMA) Universidad de Navarra Who's behind this story?

Stephanie Baum

Master's in TESOL from The New School. Passionate about language learning and editing science news on biology and space exploration. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Identification of new molecular markers for multiple myeloma paves path for more precise therapies (2026, July 1) retrieved 1 July 2026 from https://medicalxpress.com/news/2026-07-identification-molecular-markers-multiple-myeloma.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.